Evolve Private Wealth LLC Reduces Holdings in Becton, Dickinson and Company $BDX

Evolve Private Wealth LLC lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 60.8% during the second quarter, Holdings Channel reports. The firm owned 2,512 shares of the medical instruments supplier’s stock after selling 3,899 shares during the quarter. Evolve Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $381,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Varma Mutual Pension Insurance Co boosted its stake in Becton, Dickinson and Company by 10.8% during the 2nd quarter. Varma Mutual Pension Insurance Co now owns 80,821 shares of the medical instruments supplier’s stock worth $12,231,000 after purchasing an additional 7,900 shares during the period. TRB Wealth Management LLC acquired a new position in Becton, Dickinson and Company in the second quarter valued at $229,000. Korea Investment CORP raised its holdings in shares of Becton, Dickinson and Company by 130.1% in the second quarter. Korea Investment CORP now owns 102,924 shares of the medical instruments supplier’s stock valued at $15,575,000 after buying an additional 58,200 shares during the last quarter. Callan Family Office LLC boosted its stake in shares of Becton, Dickinson and Company by 5.9% during the second quarter. Callan Family Office LLC now owns 3,019 shares of the medical instruments supplier’s stock worth $457,000 after buying an additional 169 shares during the period. Finally, Heartland Advisors Inc. boosted its stake in shares of Becton, Dickinson and Company by 11.5% during the second quarter. Heartland Advisors Inc. now owns 129,740 shares of the medical instruments supplier’s stock worth $19,634,000 after buying an additional 13,396 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $189.87 on Wednesday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average price is $163.37 and its 200 day moving average price is $160.60. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The stock has a market cap of $52.32 billion, a price-to-earnings ratio of 57.19, a PEG ratio of 13.44 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. UBS Group assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price on the stock. The Goldman Sachs Group cut their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Finally, Jefferies Financial Group restated a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $185.67.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,704 shares of company stock valued at $1,963,618 over the last three months. 0.40% of the stock is currently owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.